Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a key hormone be missing in septic shock?

NCT ID NCT07721974

Knowledge-focused Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

Septic shock is a life-threatening condition with high mortality. This study investigates whether patients with septic shock have a deficiency of angiotensin II, a hormone that helps regulate blood pressure. Researchers will measure hormone levels in blood and urine samples from 320 adults with septic shock, as well as from patients with less severe infections or other types of shock. The goal is to determine how common this deficiency is and whether it is specific to septic shock.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If this study confirms that many septic shock patients have low angiotensin II, it could support using angiotensin II as a targeted treatment.
What could go wrong
This is an observational study, not a treatment trial. It will measure hormone levels but cannot prove that correcting them improves outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 320 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Oct 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Adult patients with septic shock: * Proven or suspected infection. * Persistent arterial hypotension requiring norepinephrine administration to maintain a mean arterial pressure above 65 mmHg despite adequate fluid resuscitation. * Hyperlactatemia \> 2 mmol/L. Adult critically ill control patients with sepsis without circulatory failure: * Proven or suspected infection. * Absence of persistent arterial hypotension requiring norepinephrine administration to maintain a mean arterial pressure above 65 mmHg. * An increase of at least 2 points in the SOFA score attributable to infection. Adult critically ill control patients with cardiogenic shock: * Acute cardiac disease, such as myocardial infarction. * Persistent arterial hypotension requiring norepinephrine administration to maintain a mean arterial pressure above 65 mmHg despite adequate fluid resuscitation. * Low cardiac output: cardiac index \< 2.2 L/min/m² or the need for inotropic support (including norepinephrine) to maintain a cardiac index \> 2.2 L/min/m². * Elevated left ventricular filling pressures, measured invasively or estimated by echocardiography. * Hyperlactatemia \> 2 mmol/L. Adult healthy volunteers: * Absence of active or chronic disease. * Absence of long-term medication use. * No surgery or medication intake within the previous month. * Absence of ongoing pregnancy. * Non-smoker. Exclusion Criteria: * Patients deprived of liberty by judicial or administrative decision. * Patients admitted to the intensive care unit for more than 48 hours. * Patients previously enrolled in an interventional study with overlapping follow-up. * Patients benefiting from State Medical Aid (AME).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiogenic shock are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cardiogenic shock infectious disease with sepsis toxic shock syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Septic shock

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.